SS Innovations International, Inc. annual report, FY2018

Business context and reporting period

The supplied filing is AVRA Medical Robotics, Inc.’s Form 10-K for the fiscal year ended December 31, 2018—not a filing under the requested company name, SS Innovations International, Inc., and not a standalone fourth-quarter report. AVRA was a development-stage medical robotics company focused initially on a robotic skin-resurfacing system. It had no products ready for retail marketing and had generated no revenue.

Key financial metrics

Gross margin is not applicable because there were no sales. Current assets were $41,546 against current liabilities of $449,783, a working-capital deficit of $408,237. All reported liabilities were current; the balance sheet lists $15,000 due to a majority shareholder and $15,000 of promissory notes. Cash declined by $416,856 during 2018. Financing activities provided $50,000, while investing activities used $23,568.

Changes versus the prior comparable period

Net loss narrowed by about 7% from 2017, mainly reflecting lower operating expenses and no interest expense in 2018; G&A fell modestly and R&D declined. Despite lower operating cash use, year-end cash fell sharply as financing proceeds were much lower than in 2017. Liabilities increased and the company moved from positive stockholders’ equity to a deficit.

Outlook, risks and unusual items

• Management said substantial additional funding would be needed for research, development and operations. There were no committed funding sources, and the auditor’s report cited substantial doubt about the company’s ability to continue as a going concern.
• The company was developing a prototype with the University of Central Florida; the research agreement was extended, with no additional payment required under the amendment. Prototype completion, regulatory clearance and commercialization remained uncertain. Management estimated a potential FDA process of six months to two years and $200,000–$500,000, but this was not a firm forecast.
• Management described plans to raise capital and potentially pursue development partnerships, without quantified revenue, earnings or cash-flow guidance. Failure to obtain financing could curtail operations; new financing could dilute existing shareholders.
• Disclosure controls were reported ineffective at the reasonable-assurance level due to material weaknesses, including documentation/testing and segregation-of-duties issues. Remediation was contingent on available resources.
• The common stock traded on OTCQB, with a sporadic and extremely limited market. The company reported no pending or threatened legal proceedings and no material off-balance-sheet arrangements.
• Subsequent-event disclosures describe additional borrowings and equity-related actions in 2019. The filing’s narrative also refers to certain loans as obtained in December 2019, despite the report being signed in April 2019; the timing is unclear in the supplied text.

Important facts for investors to verify

• Confirm the intended issuer: the supplied 10-K is for AVRA Medical Robotics, Inc., not SS Innovations International, Inc.
• Confirm the intended period: this is an annual report for the year ended December 31, 2018, rather than a separate Q4 filing.
• Reconcile the 2018 R&D expense discrepancy ($27,121 in MD&A versus $27,125 in the audited statements) and the MD&A’s “unaudited” label for balance-sheet data.
• Review the going-concern uncertainty, cash runway, current obligations, and the availability and terms of subsequent financing.
• Verify prototype progress, the applicable FDA pathway and requirements, and the timing and cost of any regulatory submission.
• Clarify the inconsistent or apparently future-dated loan references in the subsequent-event and liquidity disclosures.